The stock of Agenus Inc (NASDAQ:AGEN) is a huge mover today! About 391,262 shares traded hands. Agenus Inc (NASDAQ:AGEN) has risen 20.56% since April 11, 2016 and is uptrending. It has outperformed by 14.42% the S&P500.
The move comes after 5 months positive chart setup for the $468.08 million company. It was reported on Nov, 11 by Barchart.com. We have $9.90 PT which if reached, will make NASDAQ:AGEN worth $435.31 million more.
Agenus Inc (NASDAQ:AGEN) Ratings Coverage
Out of 5 analysts covering Agenus (NASDAQ:AGEN), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Agenus has been the topic of 8 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Maxim Group upgraded the shares of AGEN in a report on Friday, March 11 to “Buy” rating. Jefferies maintained it with “Buy” rating and $7 target price in Friday, July 29 report. The firm has “Buy” rating given on Thursday, October 27 by Maxim Group. The company was maintained on Monday, July 27 by MLV. The firm has “Hold” rating given on Tuesday, October 27 by Maxim Group. As per Wednesday, December 16, the company rating was initiated by Jefferies. H.C. Wainwright downgraded the stock to “Neutral” rating in Friday, October 28 report. The stock has “Market Outperform” rating given by JMP Securities on Wednesday, March 9.
According to Zacks Investment Research, “Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company’s product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.8 in 2016 Q2. Its down 0.58, from 1.38 in 2016Q1. The ratio dropped, as 15 funds sold all Agenus Inc shares owned while 26 reduced positions. 7 funds bought stakes while 26 increased positions. They now own 34.68 million shares or 5.72% less from 36.79 million shares in 2016Q1.
Bnp Paribas Arbitrage Sa holds 2,831 shares or 0% of its portfolio. Geode Capital Mngmt Ltd Company owns 511,363 shares or 0% of their US portfolio. Rhumbline Advisers has 0% invested in the company for 94,272 shares. Springbok Capital Mgmt Ltd Liability Corp holds 0% of its portfolio in Agenus Inc (NASDAQ:AGEN) for 1,100 shares. Citigroup has 16,651 shares for 0% of their US portfolio. The Pennsylvania-based Vanguard Grp Inc Inc has invested 0% in Agenus Inc (NASDAQ:AGEN). Artal Grp Sa last reported 1.00 million shares in the company. Sei Invs reported 2,666 shares or 0% of all its holdings. Blackrock holds 9,888 shares or 0% of its portfolio. Kistler last reported 200 shares in the company. Rtw Investments Limited Liability Corporation has invested 3.36% of its portfolio in Agenus Inc (NASDAQ:AGEN). National Planning Corp last reported 10,000 shares in the company. Commercial Bank Of Montreal Can last reported 0% of its portfolio in the stock. Pnc Financial Svcs Group Inc accumulated 11,397 shares or 0% of the stock. Financial Bank Of New York Mellon Corp holds 342,133 shares or 0% of its portfolio.
Insider Transactions: Since September 6, 2016, the stock had 1 buying transaction, and 0 selling transactions for $188,700 net activity. The insider WIINBERG ULF bought 30,000 shares worth $188,700.
More important recent Agenus Inc (NASDAQ:AGEN) news were published by: Fool.com which released: “Why Fret Over Agenus Inc. Q3 Results?” on October 27, 2016, also Fool.com published article titled: “Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc.”, Prnewswire.com published: “Agenus to Report Third Quarter 2016 Financial Results on October 27, 2016 …” on October 20, 2016. More interesting news about Agenus Inc (NASDAQ:AGEN) was released by: Prnewswire.com and their article: “Agenus Appoints James Gorman, M.D., Ph.D. as Vice President of Strategic …” with publication date: October 18, 2016.
AGEN Company Profile
Agenus Inc. (Agenus), incorporated on November 10, 1999, is an immuno-oncology company. The Firm is engaged in discovering and developing treatments for patients with cancer. The Company’s approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Firm has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP) vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. The Firm has programs targeting GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed targets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.